CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $49
Atricure's Market Strength and Innovation Justify Buy Rating
Oppenheimer Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $32
Navigating 6 Analyst Ratings For AtriCure
AtriCure Price Target Cut to $53.00/Share From $58.00 by BTIG
JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $30
A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $26 to $60
AtriCure Price Target Cut to $40.00/Share From $65.00 by Piper Sandler
AtriCure Analyst Ratings
Piper Sandler Remains a Buy on Atricure (ATRC)
Analysts Are Bullish on These Healthcare Stocks: Incyte (INCY), Atricure (ATRC)
AtriCure's Growth Prospects and Buy Rating Despite Short-Term Challenges
Analyst Ratings For AtriCure
AtriCure Analyst Ratings
Atricure's Competitive Landscape Clears: A Buy Rating Amid Delayed Threats and Growth Prospects
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)
AtriCure Analyst Ratings
AtriCure Analyst Ratings
AtriCure's Strong Growth and Market Position Justify Buy Rating
Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)